Reducing METTL1 expression in prostate cancer models results in increased proinflammatory immune cell infiltration and improves the response to immunotherapy, suggesting METTL1 as a potential target to improve chemotherapy sensitivity.317. Here, METTL1 is linked to prostate cancer.